Jeremy Cotliar, MD
Ophthalmology · New York, NYNPI 1063678332
Payments from drug & device makers
Across 496 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$3K
- Bausch & Lomb Americas Inc.$2K
- Kala Pharmaceuticals, Inc.$920
- Sun Pharmaceutical Industries Inc.$585
- Novartis$511
- plus $2K from 20 others
What the payments were for
- Food & beverage$11,920100%
- Education$180%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 162 | $3,051 |
| AbbVie(2 entities) | 117 | $2,762 |
| Bausch & Lomb Americas Inc. | 34 | $1,877 |
| Kala Pharmaceuticals, Inc. | 41 | $920 |
| Sun Pharmaceutical Industries Inc. | 35 | $585 |
| Novartis | 27 | $511 |
| Oyster Point Pharma, Inc. | 12 | $407 |
| Aerie Pharmaceuticals, Inc. | 3 | $303 |
| Biotissue Holdings Inc. | 13 | $260 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $155 |
| Dompe US, Inc. | 5 | $144 |
| Shire North American Group Inc | 7 | $138 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $135 |
| Galderma Laboratories, L.p. | 1 | $105 |
| Harrow Eye, LLC | 3 | $91 |
| Sight Sciences, Inc. | 1 | $90 |
| Tarsus Pharmaceuticals, Inc. | 5 | $88 |
| Eyevance Pharmaceuticals LLC | 3 | $66 |
| Ocular Therapeutix, Inc. | 3 | $62 |
| Astellas Pharma US Inc | 2 | $49 |
| Glaukos Corporation | 1 | $45 |
| Thea Pharma Inc. | 2 | $36 |
| Rxsight Inc | 1 | $23 |
| Ivantis, Inc | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$927
- LUMIGAN$497
- TORIC$261
- COMBIGAN$249
- IC-8 Apthera IOL$146
- XEN GLAUCOMA TREATMENT SYSTEM$126
- RESTASIS$125
- Rocklatan$125
- Rhopressa$125
- MIEBO$121
- SIMBRINZA$118
- TYRVAYA$115
- ENVISTA ENVY IOL$106
- Luxor$104
- Constellation$104
- Clareon PanOptix Pro$103
How this compares
$11,958 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,078 | $1,157,899 |
| XiidraLifitegrast | 1,081 | $1,103,047 |
| EysuvisLoteprednol Etabonate | 1,179 | $562,789 |
| LumiganBimatoprost | 510 | $272,772 |
| CombiganBrimonidine Tartrate/Timolol | 400 | $158,572 |
| MieboPerfluorohexyloctane/Pf | 148 | $110,202 |
| TyrvayaVarenicline Tartrate | 163 | $102,696 |
| Prednisolone Acetate | 1,439 | $77,897 |
| RocklatanNetarsudil Mesylat/Latanoprost | 161 | $70,401 |
| Cyclosporine | 186 | $58,370 |
| Restasis MultidoseCyclosporine | 72 | $50,613 |
| Alphagan PBrimonidine Tartrate | 89 | $38,023 |
| RhopressaNetarsudil Mesylate | 66 | $37,639 |
| Brimonidine Tartrate | 432 | $28,647 |
| Ketorolac Tromethamine | 959 | $24,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P | $2,762 | $1,677,8782,149 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,877 | $1,220,5691,250 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $920 | $562,7891,179 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $303 | $108,040227 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $407 | $102,696163 claims |
| AlconSimbrinza | $3,051 | $13,92265 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $585 | $12,78515 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBepreve, Loteprednol Etabonate | $155 | $7,52434 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $66 | $6,34928 claims |
| NovartisIlevro | $511 | $4,86813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.